BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
Cantor Fitzgerald
Harvard Business School

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,474,787

« Back to Dashboard

Summary for Patent: 4,474,787

Title: 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof
Abstract:There are described compounds of formula I ##STR1## in which an adjacent pair of R.sub.5, R.sub.6, R.sub.7 and R.sub.8 form a chain --COCH.dbd.CE--O--, and the remainder of R.sub.5, R.sub.6, R.sub.7 and R.sub.8, which may be the same or different, each represent hydrogen, hydroxy, alkyl, halogen, alkenyl, alkoxy, or --NR.sub.1 R.sub.2 in which R.sub.1 and R.sub.2, which are the same or different, are each hydrogen or alkyl, Rg is hydrogen, alkyl, alkenyl or phenyl-alkyl, and E is --COOH, a 5-tetrazolyl group or an (N-tetrazol-5-yl) carboxamido group, and pharmaceutically acceptable derivatives thereof. There are also described processes for making the compounds and pharmaceutical, e.g. anti-allergic, compositions containing the compounds.
Inventor(s): Cairns; Hugh (Loughborough, GB2), Cox; David (Loughborough, GB2)
Assignee: Fisons Limited (GB2)
Application Number:06/344,982
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Dosage form;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,474,787

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom18597/77May 04, 1977
United Kingdom48565/77Nov 04, 1977
United Kingdom16168/78Apr 25, 1978

International Patent Family for Patent: 4,474,787

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Finland70899► Subscribe
Finland781346► Subscribe
Spain8707222► Subscribe
Spain556218► Subscribe
Spain469391► Subscribe
Denmark158266► Subscribe
Denmark190178► Subscribe
Germany2819215► Subscribe
Cyprus1279► Subscribe
Switzerland634071► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Cantor Fitzgerald
Daiichi Sankyo
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus